Dyslipidemia, characterized by elevated low density lipoprotein-cholesterol (LDL-C), is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of compounds that inhibit PCSK9 and are a class of new lipid-lowering drugs. It interferes with the recycling of low density lipoprotein receptor (LDLR), thus hindering LDL-C clearance mediated by LDLR, which brings new hope for lipid-lowering therapy. This article reviewed the discovery, structure, regulation and biological functions of PCSK9 targets, focusing on the pharmacodynamics, pharmacokinetics and recent clinical research progress of monoclonal antibodies and small interfering RNA drugs, in order to provide reference for clinical diagnosis and treatment.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |